MIT's 'Mini Livers' Could Revolutionize Treatment for Chronic Liver Disease

Scientists at MIT have created injectable 'mini livers' that could help patients with chronic liver disease. The new approach aims to support failing organs without the need for a full transplant. Thousands of Americans currently wait for liver transplants, but donated organs remain in short supply.

The technology involves injecting clusters of liver cells, called 'satellite livers,' into the body. These cells act as a booster, taking over essential functions without replacing the original organ. In tests on mice, the injected cells survived for at least two months and produced key liver proteins.

Many patients with severe liver failure cannot receive transplants due to poor health. With over 10,000 Americans on the waiting list, demand far exceeds available organs. The total US organ transplant list had around 123,000 names in 2015, though recent figures for liver patients remain unclear.

The MIT team's work offers a potential alternative for those unable to access transplants. If successful in humans, the 'mini livers' could extend survival and improve quality of life. Further testing will determine how long the cells remain effective and whether they can fully support liver function.